Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Operating Expenses of $10.0 million for Q1 2026, down 17.55% year-over-year from $12.2 million in Q1 2025, and up 0.51% quarter-over-quarter from $10.0 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Operating Expenses history runs 7 years deep, the most recent figure standing at $10.0 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 17.55% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $37.8 million (down 27.98% YoY), while the FY2025 annual figure was $39.9 million, down 26.5% from the prior year.
- Operating Expenses for Q1 2026 stood at $10.0 million, up from $10.0 million in the prior quarter.
- The five-year high for Operating Expenses was $18.3 million in Q2 2023, with the low at $7.3 million in Q3 2025.
- The 5-year median for Operating Expenses is $13.8 million (2022), against an average of $13.8 million.
- Peak annual rise in Operating Expenses reached 131.44% in 2022, while the deepest fall reached 41.18% in 2022.
- Rani Therapeutics Holdings' Operating Expenses stood at $17.5 million in 2022, then declined by 23.16% to $13.4 million in 2023, then grew by 19.0% to $16.0 million in 2024, then slumped by 37.47% to $10.0 million in 2025, then rose by 0.51% to $10.0 million in 2026.
- Business Quant data shows RANI's Operating Expenses at $10.0 million in Q1 2026, $10.0 million in Q4 2025, and $7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 541.02 Mn |
| 10 | Rani Therapeutics Holdings | 164.82 Mn | 164.82 Mn | - | 10.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.54 Mn |
| Mar 31, 2026 | 10.05 Mn |
| Dec 31, 2025 | 10.00 Mn |
| Sep 30, 2025 | 7.26 Mn |
| Jun 30, 2025 | 10.51 Mn |
| Mar 31, 2025 | 12.19 Mn |
| Dec 31, 2024 | 15.99 Mn |
| Sep 30, 2024 | 11.80 Mn |
| Jun 30, 2024 | 12.52 Mn |
| Mar 31, 2024 | 14.03 Mn |
| Dec 31, 2023 | 13.43 Mn |
| Sep 30, 2023 | 17.86 Mn |
| Jun 30, 2023 | 18.29 Mn |
| Mar 31, 2023 | 16.52 Mn |
| Dec 31, 2022 | 17.48 Mn |
| Sep 30, 2022 | 16.34 Mn |
| Jun 30, 2022 | 15.85 Mn |
| Mar 31, 2022 | 13.78 Mn |
| Dec 31, 2021 | 13.36 Mn |
| Sep 30, 2021 | 27.78 Mn |